Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813470 | 0.88 | UGT8 (0.71) | UGT8 | |
| SCHEMBL30845445 | 0.88 | UGT8 (0.71) | UGT8 | |
| SCHEMBL21813861 | 0.88 | KDM4E (0.59) | KDM4EUGT8 | |
| SCHEMBL30845417 | 0.88 | KDM4E (0.59) | KDM4EUGT8 | |
| SCHEMBL21828479 | 0.87 | KDM4E (0.58) | KDM4EUGT8 | |
| SCHEMBL21828531 | 0.87 | KDM4E (0.58) | KDM4EUGT8 | |
| SCHEMBL21814067 | 0.87 | KDM4E (0.58) | KDM4EUGT8 | |
| SCHEMBL4817911 | 0.87 | KDM4E (0.67) | KDM4EUGT8 | |
| SCHEMBL21813383 | 0.85 | UGT8 (0.64) | KDM4EUGT8 | |
| SCHEMBL21813885 | 0.85 | UGT8 (0.66) | KDM4EUGT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-3861000-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | Genzyme Corporation (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020072504-A1 | THIENO[3,2-B]PYRIDINE DERIVATIVES AS UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION (US) | 2020-04-09 | — | — | WO | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | KDM4E 647/4885UGT8 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.